Literature DB >> 18305218

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability.

Tilmann Bochtler1, Ute Hegenbart, Friedrich W Cremer, Christiane Heiss, Axel Benner, Dirk Hose, Marion Moos, Jelena Bila, Claus R Bartram, Anthony D Ho, Hartmut Goldschmidt, Anna Jauch, Stefan O Schonland.   

Abstract

Chromosomal aberrations (CAs) have emerged as important pathogenetic and prognostic factors in plasma cell disorders. Using interphase fluorescence in situ hybridization (FISH) analysis, we evaluated CAs in a series of 75 patients with amyloid light chain amyloidosis (AL) as compared with 127 patients with monoclonal gammopathy of unknown significance (MGUS). We investigated IgH translocations t(11;14), t(4;14), and t(14;16) as well as gains of 1q21, 11q23, and 19q13 and deletions of 8p21, 13q14, and 17p13, detecting at least one CA in 89% of the patients. Translocation t(11;14) was the most frequent aberration in AL, with 47% versus 26% in MGUS (P = .03), and was strongly associated with the lack of an intact immunoglobulin (P < .001), thus contributing to the frequent light chain subtype in AL. Other frequent aberrations in AL included deletion of 13q14 and gain of 1q21, which were shared by MGUS at comparable frequencies. The progression to multiple myeloma (MM) stage I was paralleled by an increased frequency of gain of 1q21 (P = .001) in both groups. Similar branching patterns were observed in an oncogenetic tree model, indicating a common mechanism of underlying karyotypic instability in these plasma cell disorders.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18305218     DOI: 10.1182/blood-2007-11-122101

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Julieta Panero; Jorge Arbelbide; Dorotea Beatriz Fantl; Hernán García Rivello; Dana Kohan; Irma Slavutsky
Journal:  Mol Med       Date:  2010-07-14       Impact factor: 6.354

2.  Donor lymphocyte infusions in amyloid light chain amyloidosis: induction of a "graft-versus-plasma cell-dyscrasia effect".

Authors:  Stefan O Schonland; Nicolaus Kröger; Christine Wolschke; Peter Dreger; Anthony D Ho; Ute Hegenbart
Journal:  Haematologica       Date:  2009-01-27       Impact factor: 9.941

3.  Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.

Authors:  Brendan M Weiss; Joseph Hebreo; Daniel V Cordaro; Mark J Roschewski; Thomas P Baker; Kevin C Abbott; Stephen W Olson
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

4.  Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Authors:  Tilmann Bochtler; Maximilian Merz; Thomas Hielscher; Martin Granzow; Korbinian Hoffmann; Alwin Krämer; Marc-Steffen Raab; Jens Hillengass; Anja Seckinger; Christoph Kimmich; Tobias Dittrich; Carsten Müller-Tidow; Dirk Hose; Hartmut Goldschmidt; Ute Hegenbart; Anna Jauch; Stefan O Schönland
Journal:  Blood Adv       Date:  2018-10-23

Review 5.  New developments in diagnosis, risk assessment and management in systemic amyloidosis.

Authors:  Iuliana Vaxman; Angela Dispenzieri; Eli Muchtar; Morie Gertz
Journal:  Blood Rev       Date:  2019-11-02       Impact factor: 8.250

6.  Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Authors:  Iman Meziane; Stefanie Huhn; Miguel Inacio da Silva Filho; Niels Weinhold; Chiara Campo; Jolanta Nickel; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Stefano Landi; Jonathan S Mitchell; David Johnson; Anna Jauch; Gareth J Morgan; Richard Houlston; Hartmut Goldschmidt; Paolo Milani; Giampaolo Merlini; Dorota Rowcieno; Philip Hawkins; Ute Hegenbart; Giovanni Palladini; Ashutosh Wechalekar; Asta Försti; Stefan O Schönland; Kari Hemminki
Journal:  Haematologica       Date:  2017-07-04       Impact factor: 9.941

Review 7.  Molecular pathogenesis of multiple myeloma and its premalignant precursor.

Authors:  W Michael Kuehl; P Leif Bergsagel
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

8.  Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone.

Authors:  Nelson Leung; Stephan D Thomé; Angela Dispenzieri
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

9.  Discovery platform for inhibitors of IgH gene enhancer activity.

Authors:  Nathan G Dolloff
Journal:  Cancer Biol Ther       Date:  2018-11-27       Impact factor: 4.742

10.  Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.

Authors:  Alan H Bryce; Rhett P Ketterling; Morie A Gertz; Martha Lacy; Ryan A Knudson; Steven Zeldenrust; Shaji Kumar; Suzanne Hayman; Francis Buadi; Robert A Kyle; Philip R Greipp; John A Lust; Stephen Russell; S Vincent Rajkumar; Rafael Fonseca; Angela Dispenzieri
Journal:  Haematologica       Date:  2009-02-11       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.